Combining MAP‐1:CD35 or MAP‐1:CD55 fusion proteins with pattern‐recognition molecules as novel targeted modulators of the complement cascade

다국어 초록 (Multilingual Abstract)

Dysregulation of the complement system is involved in the pathogenesis of several diseases, and its inhibition has been shown to be a feasible therapeutic option. Therefore, there is an interest in the development of complement modulators to treat complement activation–related inflammatory pathologies. Mannose‐binding lectin (MBL)/ficolin/collectin‐associated protein‐1 (MAP‐1) is a regulatory molecule of the lectin pathway (LP), whereas complement receptor 1 (CD35) and decay‐accelerating factor (CD55) are membrane‐anchored regulators with effects on the central effector molecule C3. In this study, we developed 2 novel soluble chimeric inhibitors by fusing MAP‐1 to the 3 first domains of CD35 (CD351–3) or the 4 domains of CD55 (CD551–4) to modulate the complement cascade at 2 different stages. The constructs showed biologic properties similar to those of the parent molecules. In functional complement activation assays, the constructs were very efficient in inhibiting LP activation at the level of C3 and in the formation of terminal complement complex. This activity was enhanced when coincubated with recombinant LP recognition molecules MBL and ficolin‐3. Recombinant MAP‐1 fusion proteins, combined with recombinant LP recognition molecules to target sites of inflammation, represent a novel and effective therapeutic approach involving the initiation and the central and terminal effector functions of the complement cascade.—Pérez‐Alós, L., Bayarri‐Olmos, R., Skjoedt, M.‐O., Garred, P. Combining MAP‐1:CD35 or MAP‐1:CD55 fusion proteins with pattern‐recognition molecules as novel targeted modulators of the complement cascade. FASEB J. 33, 12723–12734 (2019). www.fasebj.org